Kumar Arvind, Pulle Mohan Venkatesh, Asaf Belal Bin, Shivnani Ganesh, Maheshwari Arun, Kodaganur Srinivas Gopinath, Puri Harsh Vardhan, Bishnoi Sukhram
Centre for Chest Surgery, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Department of Cardiac Surgery, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Indian J Surg Oncol. 2020 Dec;11(4):711-719. doi: 10.1007/s13193-020-01204-5. Epub 2020 Sep 4.
This study was aimed at reporting the surgical management of superior vena cava invasion in patients with locally advanced thymoma and to evaluate surgical and survival outcomes. This is a retrospective analysis of 12 patients operated for superior vena cava resection for locally advanced thymoma over 8 years in a thoracic surgery centre in India. An analysis of peri-operative variables including complications was carried out. The influence of various predictors on survival was assessed by log-rank test. Intra-operatively, superior vena cava (SVC) alone was involved in 3 (25%) cases, SVC with BCV involvement was there in 8 cases (66.7%) and in 1 patient, the SVC involvement extended into the right atrium also. In all cases, the tumour was resected en bloc with the involved part of SVC. Repair with primary closure was sufficient in 2 cases (16.6%) in view of < 1/3rd of circumferential involvement. However, in remaining 10 cases, SVC was replaced with PTFE graft (single graft in 6 cases, Y-graft in 2 cases and twin grafts in 2 cases). No peri-operative deaths. Overall survival (OS) at 1, 3 and 5 years was 100%, 91.6% and 83.3%, respectively. Myasthenia gravis and higher Masaoka stage (IV A) of the disease were poor predictors of survival. Superior vena cava resection and reconstruction is a feasible and oncologically superior option in invasive thymoma with SVC involvement. This challenging surgical procedure should only be attempted by an experienced team of thoracic and cardiac surgeons at high-volume centre to achieve best outcomes.
本研究旨在报告局部晚期胸腺瘤患者上腔静脉侵犯的外科治疗情况,并评估手术及生存结果。这是一项对印度一家胸外科中心8年间因局部晚期胸腺瘤接受上腔静脉切除手术的12例患者的回顾性分析。对包括并发症在内的围手术期变量进行了分析。通过对数秩检验评估各种预测因素对生存的影响。术中,单纯上腔静脉(SVC)受累3例(25%),上腔静脉合并无名静脉受累8例(66.7%),1例患者上腔静脉受累还延伸至右心房。所有病例中,肿瘤均与受累的上腔静脉部分整块切除。鉴于周向受累<1/3,2例(16.6%)患者一期缝合修复即可。然而,其余10例患者中,上腔静脉用聚四氟乙烯移植物替代(6例用单根移植物,2例用Y形移植物,2例用双根移植物)。无围手术期死亡。1年、3年和5年的总生存率分别为100%、91.6%和83.3%。重症肌无力和疾病的较高Masaoka分期(IV A期)是生存的不良预测因素。对于侵犯上腔静脉的侵袭性胸腺瘤,上腔静脉切除重建是一种可行且在肿瘤学上更优的选择。这种具有挑战性的外科手术应由经验丰富的胸心外科团队在大容量中心进行尝试,以取得最佳结果。